The agency weighed safety data and a new dosing regimen to recommend approval of the treatment for early Alzheimer's disease in certain patients.

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

Eli Lilly (NYSE:LLY) announced that its Alzheimer’s medication Kisunla (donanemab) has secured a favorable opinion from the ...

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.

Roche reported better than expected first-half operating profit, driven by strong sales of breast cancer and asthma ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Named for his dam's late veterinarian, Dr. Agne prevailed on debut in an off-the-turf event.

Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed pharmaceutical stocks on Cramer’s morning show.

Kade Anderson has emerged as the favorite to be selected No. 1 overall by the Washington Nationals in the 2025 MLB draft, but there is a possibility that high-school shortstop Eli Willits could ...